Alyssa Greenleaf, PA
Medical · Southington, CTNPI 1861896524
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $20,129 of the $25,853 with a category attached, or 77.9%. Cequr Corporation accounts for 86.5% of it on its own, with 23 other manufacturers making up the rest. Among medical clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 137 payments — averaging $188.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cequr Corporation$22K
- Dexcom, Inc.$664
- Abbott$564
- Novo Nordisk$429
- Amgen$388
- Medtronic$240
- plus $1K from 18 others
What the payments were for
- Speaking & faculty fees$20,12978%
- Travel & lodging$8393%
- Food & beverage$4,88519%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cequr Corporation | 9 | $22,352 |
| Dexcom, Inc. | 22 | $664 |
| Abbott | 18 | $564 |
| Novo Nordisk | 35 | $429 |
| Amgen | 6 | $388 |
| Medtronic | 10 | $240 |
| Tandem Diabetes Care, Inc. | 3 | $225 |
| Bayer | 4 | $176 |
| Lilly USA, LLC | 3 | $155 |
| Insulet Corporation | 5 | $117 |
| Xeris Pharmaceuticals, Inc. | 5 | $111 |
| AstraZeneca | 2 | $61 |
| Corcept Therapeutics | 2 | $60 |
| Mannkind Corporation | 1 | $44 |
| Sequel Med Tech, LLC | 2 | $42 |
| Novartis | 2 | $36 |
| Embecta Corp. | 1 | $29 |
| Sanofi-aventis U.S. LLC | 1 | $28 |
| AbbVie | 1 | $24 |
| Halozyme Inc | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| BETA Bionics, Inc. | 1 | $22 |
| Almatica Pharma LLC | 1 | $22 |
| Recordati_rare_diseases_inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$22,314
- FREESTYLE LIBRE 3$261
- TEPEZZA$232
- t:slim X2 Insulin Pump with Control-IQ$152
- DEXCOM G7 GSS (161)$126
- MINIMED 780G$114
- Kerendia$108
How this compares
$25,853 in reported general payments places this provider in the 95th percentile of 592 medical providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 319 | $485,895 |
| JardianceEmpagliflozin | 239 | $344,127 |
| MounjaroTirzepatide | 258 | $320,236 |
| TrulicityDulaglutide | 187 | $264,811 |
| FarxigaDapagliflozin Propanediol | 121 | $141,870 |
| Tresiba Flextouch U-100Insulin Degludec | 174 | $108,985 |
| Tresiba Flextouch U-200Insulin Degludec | 82 | $107,581 |
| Humalog Kwikpen U-200Insulin Lispro | 34 | $102,083 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 75 | $96,542 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 90 | $91,556 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 48 | $74,504 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 83 | $58,381 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 53 | $47,002 |
| Humalog Kwikpen U-100Insulin Lispro | 129 | $45,441 |
| TradjentaLinagliptin | 34 | $42,490 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog, Baqsimi | $155 | $642,803539 claims |
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Fiasp, Novolog | $429 | $589,638413 claims |
| AstraZenecaFarxiga | $61 | $141,870121 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $28 | $74,50448 claims |
| Cequr CorporationCequr Simplicity | $22,352 | $21,40936 claims |
| AbbVieSynthroid | $24 | $7,11369 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 592 medical providers in Connecticut.
Other medical in Southington
- Shilpa DesaiStamford$215K
- Gregory RauNew Haven$211K
- John JasinskiNorwalk$185K
- Brianna PaesanoStamford$153K
- Debra SullivanDerby$100K
- Ryan DonovanNew Haven$75K
- Jonica PagnuccoWaterbury$32K
- Mark VolpeSuffield$21K
- Josephine DiazSuffield$20K
- Marissa CarignanManchester$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.